Insmed Incorporated
INSM
Classificação em ações
#1108
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Preço da ação
$95.88
Última sincronização: 2026-10-20
Valor de mercado
$20.94B
Variação (1 dia)
0.61%
Variação (1 ano)
-42.00%
País
US
Negociar Insmed Incorporated (INSM)
Categoria
Healthcare
Receita da Insmed Incorporated (INSM)
Receita em Jun 2026 TTM: $1.14B
De acordo com os últimos relatórios financeiros da Insmed Incorporated, a receita atual da empresa (TTM) é $1.14B. Em 2023, a empresa obteve uma receita de $305.21M um aumento em relação a a receita do ano 2022, que foi de $245.36M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Insmed Incorporated de 2000 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $1.14B | 212.79% |
| 2024 | $363.71M | 19.17% |
| 2023 | $305.21M | 24.39% |
| 2022 | $245.36M | 30.19% |
| 2021 | $188.46M | 14.63% |
| 2020 | $164.41M | 20.48% |
| 2019 | $136.47M | 1,287.56% |
| 2018 | $9.84M | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | $11.50M | 0.00% |
| 2013 | $11.50M | 0.00% |
| 2012 | 0.00 | -100.00% |
| 2011 | $4.42M | -36.18% |
| 2010 | $6.92M | -33.28% |
| 2009 | $10.37M | -11.33% |
| 2008 | $11.70M | 55.39% |
| 2007 | $7.53M | 659.74% |
| 2006 | $991.00K | 656.49% |
| 2005 | $131.00K | -4.38% |
| 2004 | $137.00K | -8.67% |
| 2003 | $150.00K | -92.33% |
| 2002 | $1.96M | 560.47% |
| 2001 | $296.00K | 393.33% |
| 2000 | $60.00K | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $12.62B | 1,009.70% |
US
|
|
| $2.23B | 95.84% |
US
|
|
| $15.74B | 1,283.95% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 429.28% |
NL
|
